Andrew D. Zelenetz MD, PhD

Andrew D. Zelenetz, MD, PhD, is an Attending Physician in the Department of Medicine at Memorial Sloan Kettering Cancer Center and Professor of Medicine at Weill Cornell Medicine. Prior to that he served as the Medical Director of Quality Informatics at MSKCC, 2016-2023, Vice-Chair of Medicine for Medical Informatics from January 2013 to May 2016 and Chief of the Lymphoma Service in the Division of Hematology/Oncology at MSKCC from 1994 to December 2012.

Dr. Zelenetz received his Bachelor of Arts degree from Harvard College, his doctorate of philosophy from Harvard University's Graduate School of Arts and Sciences Division of Medical Sciences, and his medical degree from Harvard Medical School. He completed both his internship and residency in internal medicine at Stanford University Medical Center, where he also completed clinical and research fellowships in oncology.

Dr. Zelenetz has helped develop a number of the agents now approved to treat lymphoma – including 131I-tosituomab/tositumomab, bortezomib, pralatrexate, idelalisisb, obinutuzumab, zanubrutinib, and venetoclax – and, through clinical studies, he is evaluating the benefits of novel combinations of targeted agents. He has published more than 300 papers on lymphoma research in journals such as Lancet Oncology, Lancet Haematology, Blood, Journal of Clinical Oncology, and Clinical Cancer Research.

Dr. Zelenetz is a member of the American Society of Hematology, the American Society of Clinical Oncology, and the American College of Physicians. He participates in various committees: he is a member of the Alliance Lymphoma Core Committee; is the past-Chair of the Scientific Advisory Board of the Lymphoma Research Foundation. He has received the MSKCC Fellowship Teaching Excellence Award multiple times, and he received the NCCN Rodger Winn Award in 2012.

Dr. Zelenetz is Chair of the NCCN B-Cell Lymphomas Panel. He served as a member of the editorial board for JNCCN—Journal of the National Comprehensive Cancer Network and contributed to several committees and advisory boards for the NCCN Oncology Research Program.